QA ameliorated UC through the inhibition of two TLR4‐NF‐κB and NF‐κB‐INOS‐NO signaling pathways, which results in the reduction of colitis complications, including oxidative stress, inflammation, apoptosis and histopathological injuries in rats. This evidence concerns the gene NFKB1 and colitis.